BTOG wishes to inform members of a new NICE release that has been published today.
NICE has recommended amivantamab plus lazertinib, within its marketing authorisation, as an option for untreated advanced non-small-cell lung
cancer (NSCLC) in adults whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.
For full details and the documents, please see the NICE website:
BTOG wishes to inform members of a new NICE release that has been published today. Following review of the original technical appraisal, NICE no longer recommend sotorasib for treating KRAS G12C mutation-positive locally advanced or metastatic non-small-cell...
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended serplulimab with carboplatin and etoposide within its marketing authorisation, as an option for untreated extensive-stage small cell lung cancer in adults....
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended cemiplimab with platinum-based chemotherapy - it can be used as an option for untreated non-small-cell lung cancer (NSCLC) in adults: if they would otherwise...
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended amivantamab with carboplatin and pemetrexed during the managed access period as an option for untreated advanced non-small-cell lung cancer (NSCLC) with...
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended osimertinib, within its marketing authorisation, as an option to treat unresectable locally advanced (stage 3) non-small-cell lung cancer (NSCLC) in adults....
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended encorafenib plus binimetinib as an option to treat BRAF V600E mutation-positive advanced non-small-cell lung cancer (NSCLC) in adults, only if it is used at...
BTOG wishes to inform members of a new NICE release that has been published today for nivolumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. NICE has recommended nivolumab...
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended Lorlatinib as an option for ALK-positive advanced non-small-cell lung cancer in adults who have not had an ALK inhibitor. There is a commercial access agreement for...
BTOG wishes to inform members of a new NICE release that has been published today.NICE has recommended Durvalumab, within its marketing authorisation, as an option to treat limited-stage small-cell lung cancer that has not progressed after platinum-based...
BTOG can confirm that NICE has released draft guidance as follows: Osimertinib should not be used for the maintenance treatment of locally advanced (stage 3) unresectable non-small cell lung cancer (NSCLC) in adults when the tumours have epidermal growth factor...